Back to Market返回行情

BIO Bio-Rad Laboratories, Inc.

USHealthcare
$294.96+3.91%OpenMarket Cap: $7.97B

As of 2026-07-09 11:34

Why BIO matters now

Bio-Rad Laboratories, Inc. (BIO) is a US stock in Healthcare. The latest InvestLog snapshot shows $294.96 with +3.91% on the session and $7.97B in market capitalization; recent performance reads 1-month +0.49% and YTD -6.78%.

The latest financial table shown here is Q1 2026, with revenue of $592.1M, net income of $-527.1M, and EPS of $-19.55. Investors can compare that operating picture with valuation signals such as P/E 9.92 and FCF yield 4.7%.

The latest indexable market news headline is "BIO-key Regains Compliance with Nasdaq Listing Rules; Nasdaq Trading Resumes on Wednesday, July 8th" from GlobeNewsWire.

Additional event context on this page matters because analyst consensus is Hold with a median target of $320.00; recent insider activity includes ENGELHARDT EVA ANETTE filing S-Sale. These signals are research inputs, not a recommendation.

Valuation

P/E (TTM)

9.92

PEG

0.07

P/B

1.11

P/S

2.95

EV/EBITDA

18.11

DCF Value

$-155.06

FCF Yield

4.7%

Div Yield

0.0%

Margins & Returns

Gross Margin

51.9%

Operating Margin

9.2%

Net Margin

6.5%

ROE

2.4%

ROA

1.7%

ROIC

2.0%

Financials

PeriodRevenueNet IncomeEPS
Q1 2026$592.1M$-527.1M$-19.55
Q4 2025$693.2M$720.0M$26.65
FY 2025$2.58B$759.9M$27.87
Q3 2025$653.0M$-341.9M$-12.70

Analyst Ratings

Consensus

Hold

Target (Consensus)

$321.67

Target (Median)

$320.00

Target Range

$310.00 - $335.00

Strong Buy: 1Buy: 0Hold: 4Sell: 0Strong Sell: 0
Wells FargoEqual Weight
2026-05-01
CitigroupNeutral
2026-04-07
Wells FargoEqual Weight
2026-02-16
CitigroupBuy
2025-10-30
Wells FargoEqual Weight
2025-10-30

Trading Activity

Insider Trades

ENGELHARDT EVA ANETTEofficer: EVP, President, CDG
Sell2026-05-13
ENLOE COURTNEY Cofficer: EVP, General Counsel & Sec
Sell2026-04-28
Lakkaraju Roop Kalyanofficer: EVP, Chief Financial Officer
Sell2026-04-28
ENLOE COURTNEY Cofficer: EVP, General Counsel & Sec
Sell2026-04-28
ENLOE COURTNEY Cofficer: EVP, General Counsel & Sec
Sell2026-04-28

Company Info

Sector

Healthcare

Industry

Medical - Devices

Country

US

Exchange

Beta

1.08

Bio-Rad Laboratories, Inc., established in 1952 and headquartered in Hercules, California, operates as a global provider of life science research and clinical diagnostic products. Its operations span across the United States, Canada, Europe, Asia, and Latin America. The company is organized into two primary divisions: Life Science and Clinical Diagnostics. The Life Science division is responsible for developing, manufacturing, and commercializing a diverse array of reagents, equipment, and laboratory instruments. These products are crucial for various research methodologies, biopharmaceutical manufacturing processes, and food quality testing. This segment focuses on specialized areas within the life sciences, including proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. Its clientele encompasses academic institutions (such as universities and medical schools), industrial research organizations, government agencies, pharmaceutical companies, biotechnology firms, food producers, and food testing laboratories. In contrast, the Clinical Diagnostics division designs, produces, sells, and supports a comprehensive suite of test systems, informatics solutions, diagnostic kits, and specialized quality control products for clinical laboratories. This segment provides reagents, instruments, and software specifically tailored for particular niches within the in vitro diagnostics market. Its customer base includes reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. Beyond these core segments, Bio-Rad also offers systems and products designed to separate complex chemical and biological materials, as well as to identify, analyze, and purify their individual components. The company distributes its extensive product portfolio through a combination of its direct sales force and a network of third-party distributors, agents, brokers, and resellers.